Developing Novel Genomic Risk Stratification Models in Soft Tissue and Uterine Leiomyosarcoma
CONCLUSIONS: Compared to traditional clinicopathologic models, genomic risk stratification demonstrates superior prediction of clinical outcome in STLMS and is comparable in ULMS.PMID:38488807 | DOI:10.1158/1078-0432.CCR-24-0148 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - March 15, 2024 Category: Cancer & Oncology Authors: Josephine K Dermawan Sarah Chiang Samuel Singer Bhumika Jadeja Martee L Hensley William D Tap Sujana Movva Robert G Maki Cristina R Antonescu Source Type: research

Integrative molecular analyses of the MD Anderson prostate cancer patient-derived xenograft (MDA PCa PDX) series
CONCLUSIONS: We addressed the gap in clinically relevant PCa models through comprehensive molecular characterization of MDA PCa PDXs, providing a discovery platform that integrates with patient data and benchmarked to therapeutically relevant consensus clinical groupings. This unique resource supports robust hypothesis generation and testing from basic, translational, and clinical perspectives.PMID:38488813 | DOI:10.1158/1078-0432.CCR-23-2438 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - March 15, 2024 Category: Cancer & Oncology Authors: Nicolas Anselmino Estefania Labanca Peter D A Shepherd Jiabin Dong Jun Yang Xiaofei Song Subhiksha Nandakumar Ritika Kundra Cindy J Lee Nikolaus Schultz Jianhua Zhang John C Araujo Ana M Aparicio Sumit K Subudhi Paul G Corn Louis L Pisters John F Ward Joh Source Type: research

Rintatolimod in Advanced Pancreatic Cancer enhances Anti-Tumor Immunity through Dendritic Cell-Mediated T Cell Responses
CONCLUSIONS: This study presents compelling evidence of the immune-stimulatory properties linked to TLR-3 activation through rintatolimod. Rintatolimod may break immunological tolerance by enhancing anti-tumor immunity through DC-mediated Th-cell responses. Furthermore, our findings lay the groundwork for investigating the potential synergy between TLR-3 activation and immune checkpoint inhibitor therapy to improve therapeutic outcomes.PMID:38488815 | DOI:10.1158/1078-0432.CCR-23-4085 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - March 15, 2024 Category: Cancer & Oncology Authors: Casper W F van Eijck Hassana El Haddaoui Songul Kucukcelebi Disha Vadgama Amine Fellah Dana A M Mustafa Joachim G J V Aerts Casper H J van Eijck Marcella Willemsen Source Type: research

Developing Novel Genomic Risk Stratification Models in Soft Tissue and Uterine Leiomyosarcoma
CONCLUSIONS: Compared to traditional clinicopathologic models, genomic risk stratification demonstrates superior prediction of clinical outcome in STLMS and is comparable in ULMS.PMID:38488807 | DOI:10.1158/1078-0432.CCR-24-0148 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - March 15, 2024 Category: Cancer & Oncology Authors: Josephine K Dermawan Sarah Chiang Samuel Singer Bhumika Jadeja Martee L Hensley William D Tap Sujana Movva Robert G Maki Cristina R Antonescu Source Type: research

Integrative molecular analyses of the MD Anderson prostate cancer patient-derived xenograft (MDA PCa PDX) series
CONCLUSIONS: We addressed the gap in clinically relevant PCa models through comprehensive molecular characterization of MDA PCa PDXs, providing a discovery platform that integrates with patient data and benchmarked to therapeutically relevant consensus clinical groupings. This unique resource supports robust hypothesis generation and testing from basic, translational, and clinical perspectives.PMID:38488813 | DOI:10.1158/1078-0432.CCR-23-2438 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - March 15, 2024 Category: Cancer & Oncology Authors: Nicolas Anselmino Estefania Labanca Peter D A Shepherd Jiabin Dong Jun Yang Xiaofei Song Subhiksha Nandakumar Ritika Kundra Cindy J Lee Nikolaus Schultz Jianhua Zhang John C Araujo Ana M Aparicio Sumit K Subudhi Paul G Corn Louis L Pisters John F Ward Joh Source Type: research

Rintatolimod in Advanced Pancreatic Cancer enhances Anti-Tumor Immunity through Dendritic Cell-Mediated T Cell Responses
CONCLUSIONS: This study presents compelling evidence of the immune-stimulatory properties linked to TLR-3 activation through rintatolimod. Rintatolimod may break immunological tolerance by enhancing anti-tumor immunity through DC-mediated Th-cell responses. Furthermore, our findings lay the groundwork for investigating the potential synergy between TLR-3 activation and immune checkpoint inhibitor therapy to improve therapeutic outcomes.PMID:38488815 | DOI:10.1158/1078-0432.CCR-23-4085 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - March 15, 2024 Category: Cancer & Oncology Authors: Casper W F van Eijck Hassana El Haddaoui Songul Kucukcelebi Disha Vadgama Amine Fellah Dana A M Mustafa Joachim G J V Aerts Casper H J van Eijck Marcella Willemsen Source Type: research

First-Line Anlotinib Treatment for Soft Tissue Sarcoma in Chemotherapy-Ineligible Patients: An Open-label, Single-arm, Phase 2 Clinical Trial
CONCLUSIONS: The findings suggest a potential benefit in employing front-line anlotinib to treat patients with STS, who are not eligible for cytotoxic chemotherapy. Of note, the clinical outcomes for the LPS subgroup of patients were encouraging.PMID:38483309 | DOI:10.1158/1078-0432.CCR-23-3983 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - March 14, 2024 Category: Cancer & Oncology Authors: Tao Li Ying Dong Yongzhong Wei Shoufeng Wang Yunxia Liu Jia Chen Wenhua Xiong Nong Lin Xin Huang Meng Liu Xiaobo Yan Zhaoming Ye Binghao Li Source Type: research

First-Line Anlotinib Treatment for Soft Tissue Sarcoma in Chemotherapy-Ineligible Patients: An Open-label, Single-arm, Phase 2 Clinical Trial
CONCLUSIONS: The findings suggest a potential benefit in employing front-line anlotinib to treat patients with STS, who are not eligible for cytotoxic chemotherapy. Of note, the clinical outcomes for the LPS subgroup of patients were encouraging.PMID:38483309 | DOI:10.1158/1078-0432.CCR-23-3983 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - March 14, 2024 Category: Cancer & Oncology Authors: Tao Li Ying Dong Yongzhong Wei Shoufeng Wang Yunxia Liu Jia Chen Wenhua Xiong Nong Lin Xin Huang Meng Liu Xiaobo Yan Zhaoming Ye Binghao Li Source Type: research

Translational frontiers and clinical opportunities of immunologically-fitted radiotherapy
Clin Cancer Res. 2024 Mar 13. doi: 10.1158/1078-0432.CCR-23-3632. Online ahead of print.ABSTRACTIonising radiations can have a wide range of impacts on tumour-immune interactions, which are being studied with the greatest interest and at an accelerating pace by the medical community. Despite its undeniable immunostimulatory potential, it clearly appears that radiotherapy as it is prescribed and delivered nowadays often alters the host's immunity towards a suboptimal state. This may impair the full recovery of a sustained and efficient anti-tumour immunosurveillance post-treatment. An emerging concept is arising from this a...
Source: Clinical Cancer Research - March 13, 2024 Category: Cancer & Oncology Authors: Daphn é Morel Charlotte Robert Nikos Paragios Vincent Gr égoire Eric Deutsch Source Type: research

Infiltrative vessel co-optive growth pattern induced by IQGAP3 overexpression promotes microvascular invasion in hepatocellular carcinoma
CONCLUSIONS: Our results revealed a plausible mechanism underlying IQGAP3-mediated microvascular invasion in HCC, and provided a potential target to develop therapeutic strategies to treat HCC with MVI.PMID:38470497 | DOI:10.1158/1078-0432.CCR-23-2933 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - March 12, 2024 Category: Cancer & Oncology Authors: Miaoling Tang Shuxia Zhang Meisongzhu Yang Rongni Feng Jinbin Lin Xiaohong Chen Yingru Xu Ruyuan Yu Xinyi Liao Ziwen Li Xincheng Li Man Li Qiliang Zhang Suwen Chen Wanying Qian Yuanji Liu Libing Song Jun Li Source Type: research

Polo-like kinase 1 inhibition in KRAS-mutated metastatic colorectal cancer
Clin Cancer Res. 2024 Mar 12. doi: 10.1158/1078-0432.CCR-24-0251. Online ahead of print.ABSTRACTInhibition of Polo-like kinase 1 (Plk1) is a promising new target and therapeutic strategy in metastatic colorectal cancer, especially those with KRAS mutations. New data support further development of onvansertib, and highlights the role of circulating tumor DNA in phase 1 clinical trials.PMID:38470499 | DOI:10.1158/1078-0432.CCR-24-0251 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - March 12, 2024 Category: Cancer & Oncology Authors: Justin Stebbing Andrea J Bullock Source Type: research

Cell-free DNA concentration as a biomarker of response and recurrence in HER2-negative breast cancer receiving neoadjuvant chemotherapy
CONCLUSIONS: In TNBC, cfDNA concentrations during therapy were not strongly correlated with response or prognosis. In the HR-positive/HER2-negative group, pretreatment cfDNA concentration was prognostic for DRFS. Overall, the predictive and prognostic value of cfDNA concentration was more limited than that of ctDNA.PMID:38470545 | DOI:10.1158/1078-0432.CCR-23-2928 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - March 12, 2024 Category: Cancer & Oncology Authors: Mark Jesus M Magbanua Ziad Ahmed Rosalyn W Sayaman Lamorna Brown Swigart Gillian L Hirst Christina Yau Denise M Wolf Wen Li Amy L Delson Jane Perlmutter Paula Pohlmann W Fraser Symmans Douglas Yee Nola M Hylton Laura J Esserman Angela M DeMichele Hope S R Source Type: research

Infiltrative vessel co-optive growth pattern induced by IQGAP3 overexpression promotes microvascular invasion in hepatocellular carcinoma
CONCLUSIONS: Our results revealed a plausible mechanism underlying IQGAP3-mediated microvascular invasion in HCC, and provided a potential target to develop therapeutic strategies to treat HCC with MVI.PMID:38470497 | DOI:10.1158/1078-0432.CCR-23-2933 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - March 12, 2024 Category: Cancer & Oncology Authors: Miaoling Tang Shuxia Zhang Meisongzhu Yang Rongni Feng Jinbin Lin Xiaohong Chen Yingru Xu Ruyuan Yu Xinyi Liao Ziwen Li Xincheng Li Man Li Qiliang Zhang Suwen Chen Wanying Qian Yuanji Liu Libing Song Jun Li Source Type: research

Polo-like kinase 1 inhibition in KRAS-mutated metastatic colorectal cancer
Clin Cancer Res. 2024 Mar 12. doi: 10.1158/1078-0432.CCR-24-0251. Online ahead of print.ABSTRACTInhibition of Polo-like kinase 1 (Plk1) is a promising new target and therapeutic strategy in metastatic colorectal cancer, especially those with KRAS mutations. New data support further development of onvansertib, and highlights the role of circulating tumor DNA in phase 1 clinical trials.PMID:38470499 | DOI:10.1158/1078-0432.CCR-24-0251 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - March 12, 2024 Category: Cancer & Oncology Authors: Justin Stebbing Andrea J Bullock Source Type: research

Cell-free DNA concentration as a biomarker of response and recurrence in HER2-negative breast cancer receiving neoadjuvant chemotherapy
CONCLUSIONS: In TNBC, cfDNA concentrations during therapy were not strongly correlated with response or prognosis. In the HR-positive/HER2-negative group, pretreatment cfDNA concentration was prognostic for DRFS. Overall, the predictive and prognostic value of cfDNA concentration was more limited than that of ctDNA.PMID:38470545 | DOI:10.1158/1078-0432.CCR-23-2928 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - March 12, 2024 Category: Cancer & Oncology Authors: Mark Jesus M Magbanua Ziad Ahmed Rosalyn W Sayaman Lamorna Brown Swigart Gillian L Hirst Christina Yau Denise M Wolf Wen Li Amy L Delson Jane Perlmutter Paula Pohlmann W Fraser Symmans Douglas Yee Nola M Hylton Laura J Esserman Angela M DeMichele Hope S R Source Type: research